New immunotherapy trial targets recurrent glioblastoma
January 10, 2020 | By Letisia Marquez
City of Hope has opened a first-in-human clinical trial for patients with recurrent glioblastoma. To launch the randomized trial, the National Institutes of Health awarded $3.3 million over five years to Behnam Badie, M.D. and Christine Brown, Ph.D. Brown and Badie also received $800,000 from Gateway for Cancer Research.